Cancer Genetics Revises IPO Filing, Targets $29.3M in Proceeds | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer Genetics plans to raise more than $29 million from its initial public offering, the company said in its amended Form S-1 yesterday.

In the document filed with the US Securities and Exchange Commission, the Rutherford, NJ-based cancer diagnostics firm said it anticipates net proceeds of $29.3 million from the offering. If the underwriters on the offering exercise their over-allotment options in full that figure would increase to $34.2 million.

Aegis Capital and Feltl and Co. are listed as the underwriters on the Form S-1/A.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.